EEMT™/ EEMT™ HS Esterified Estrogen and Methyltestosterone Tablets


Bottles of EEMT ™ and EEMT ™ HS

EEMT™ and EEMT™ HS are authorized generics of esterified estrogen/methyltestosterone tablets. EEMT™ and EEMT™ HS are distributed throughout all pharmaceutical wholesalers in the United States and hold first-position contract placement in several of the largest U.S. wholesalers.  Large buying groups, secondary wholesalers and pharmacy chains have distribution agreements for EEMT™ and EEMT™ HS.

Patient Information

Full Prescribing Information Including Black Box Warning

EEMT™ and EEMT™ HS Informational Flyer

Review uses, side effects, precautions and further details about EEMT™ and EEMT™ HS

Safety and Prescribing Information


Three independent case control studies have reported an increased risk  of   endometrial  cancer  in  postmenopausal  women  exposed to exogenous estrogens for prolonged   periods.1-3  This   risk was independent of  the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased  sharply since 1969 in eight different areas of the United States with population-based  cancer  reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.4The three case control studies reported that the risk of endometrial  cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment and on estrogen dose. In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible.  When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study suggests that cyclic administration of low doses of estrogen may carry less risk than continuous administration;3  it therefore appears prudent to utilize such a regimen.  Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy.  There is no evidence at present that “natural” estrogens are more or less hazardous than “synthetic” estrogens at equiestrogenic doses.


The use of female sex hormones, both estrogens and progestogens, during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a non-steroidal estrogen, have an increased risk of developing  in  later  life  a  form  of  vaginal or cervical cancer that is ordinarily extremely rare.5,6 This risk has been estimated as not greater than 4 per 1,000 exposures.7  Furthermore, a high percentage of  such exposed women (from 30 to 90 percent) have been found to have vaginal adenosis, 8-12  epithelial changes of  the vagina and cervix. Although these changes are histologically benign, it is not known whether they are precursors of malignancy. Although similar data are not available with the use of other estrogens, it cannot be presumed they would not induce similar changes.  Several reports suggest an association between intrauterine exposure to female sex hormones and congenital anomalies, including congenital heart defects and limb reduction defects. 13-16  One case control study 16  estimated a 4.7-fold increased risk of  limb reduction defects in infants exposed in utero to sex hormones (oral  contraceptives, hormone withdrawal tests for  pregnancy, or attempted treatment for threatened abortion). Some of these exposures were very short and involved only a few days of treatment. The data suggest that the risk of limb reduction defects in exposed fetuses is somewhat less than 1 per 1,000.  In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion.  There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well controlled studies that progestogens are effective for these uses. If EEMT ™ and EEMT ™ HS is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the advisability of pregnancy continuation.


EEMT ™ and EEMT ™ HS Tablets do not contain a progestin. EEMT™ and EEMT™ HS Tablets are an Estrogen/Androgen product.  Estrogens with or without progestins should not be used for the prevention of cardiovascular disease.The Women’s Health Initiative (WHI) study reported increased risks ofmyocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women during 5 years of treatment with conjugated equine estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (See CLINICAL PHARMACOLOGY, Clinical Studies).  Other doses of conjugated estrogens with medroxyprogesterone and other combinations of estrogens and progestins were not studied in the WHI and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.


Estrogens should not be used in women with any of the following conditions:

  1. Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease.
  2. Known or suspected estrogen-dependent neoplasia.
  3. Known or suspected pregnancy (See BOXED WARNINGS).
  4. Undiagnosed abnormal genital bleeding.
  5. Active thrombophlebitis or thromboembolic disorders.
  6. A past  history  of   thrombophlebitis,  thrombosis,  or  thromboembolic disorders  associated  with  previous  estrogen  use  (except  when  in  treatment of  breast malignancy).

Methyltestosterone should not be used in:

  1. The presence of severe liver damage.
  2. Pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or breast-fed infant.

Please see Full Prescribing Information, including BOXED WARNING

EEMT™ and EEMT™ HS (esterified estrogen and methyltestosterone tablets) are indicated in the treatment of moderate to severe vasomotor symptoms associated with menopause in those patients for whom estrogen-only therapy does not provide sufficient relief. This product has a black box warning because prolonged exposure to exogenous estrogens has been reported to increase the risk of endometrial carcinoma in postmenopausal women. The risk correlates to both duration of treatment and the amount of the estrogen dose. In addition, estrogens should not be used during pregnancy. EEMT™ and EEMT™ HS tablets contain estrogen but do not contain a progestin.

Estrogens should not be used for the prevention of cardiovascular disease. The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, breast cancer, pulmonary emboli and deep vein thrombosis in postmenopausal women. Estrogens should not be used in women with breast cancer, estrogen-dependent neoplasia, abnormal genital bleeding, thrombophlebitis, or thrombosis. Methyltestosterone, a synthetic form of testosterone, should not be used when severe liver damage is present or in pregnant mothers who are or are not breastfeeding.  Please review complete Patient Information.

Make Virtual Reality


© 2020 All Rights Reserved | Sitemap